Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Clearside Biomedical

Nasdaq:CLSD
Snowflake Description

Slightly overvalued with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CLSD
Nasdaq
$72M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. The last earnings update was 21 days ago. More info.


Add to Portfolio Compare Print
  • Clearside Biomedical has significant price volatility in the past 3 months.
CLSD Share Price and Events
7 Day Returns
-8%
NasdaqGM:CLSD
5.6%
US Pharmaceuticals
-1.1%
US Market
1 Year Returns
14.3%
NasdaqGM:CLSD
-7.4%
US Pharmaceuticals
-13.6%
US Market
CLSD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Clearside Biomedical (CLSD) -8% -40.5% -17.1% 14.3% -80% -
US Pharmaceuticals 5.6% -6.8% -12.8% -7.4% 4.1% 1%
US Market -1.1% -17.8% -22.5% -13.6% 4.9% 16.3%
1 Year Return vs Industry and Market
  • CLSD outperformed the Pharmaceuticals industry which returned -7.4% over the past year.
  • CLSD outperformed the Market in United States of America which returned -13.6% over the past year.
Price Volatility
CLSD
Industry
5yr Volatility vs Market

Value

 Is Clearside Biomedical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Clearside Biomedical to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Clearside Biomedical.

NasdaqGM:CLSD Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.2%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:CLSD
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.691 (1 + (1- 21%) (8.93%))
0.825
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.83
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (0.825 * 5.44%)
6.23%

Discounted Cash Flow Calculation for NasdaqGM:CLSD using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Clearside Biomedical is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:CLSD DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.23%)
2020 -19.00 Analyst x1 -17.88
2021 -1.99 Analyst x1 -1.77
2022 2.15 Analyst x1 1.79
2023 12.92 Analyst x1 10.15
2024 11.53 Analyst x1 8.53
2025 10.75 Est @ -6.77% 7.48
2026 10.30 Est @ -4.22% 6.75
2027 10.05 Est @ -2.43% 6.20
2028 9.93 Est @ -1.18% 5.76
2029 9.90 Est @ -0.3% 5.41
Present value of next 10 years cash flows $32.00
NasdaqGM:CLSD DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $9.90 × (1 + 1.74%) ÷ (6.23% – 1.74%)
$224.32
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $224.32 ÷ (1 + 6.23%)10
$122.58
NasdaqGM:CLSD Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $32.00 + $122.58
$154.58
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $154.58 / 44.87
$3.45
NasdaqGM:CLSD Discount to Share Price
Calculation Result
Value per share (USD) From above. $3.45
Current discount Discount to share price of $1.60
= -1 x ($1.60 - $3.45) / $3.45
53.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Clearside Biomedical is available for.
Intrinsic value
>50%
Share price is $1.6 vs Future cash flow value of $3.45
Current Discount Checks
For Clearside Biomedical to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Clearside Biomedical's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Clearside Biomedical's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Clearside Biomedical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Clearside Biomedical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:CLSD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.81
NasdaqGM:CLSD Share Price ** NasdaqGM (2020-04-02) in USD $1.6
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 19.89x
United States of America Market PE Ratio Median Figure of 2,943 Publicly-Listed Companies 12.9x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Clearside Biomedical.

NasdaqGM:CLSD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:CLSD Share Price ÷ EPS (both in USD)

= 1.6 ÷ -0.81

-1.98x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Clearside Biomedical is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Clearside Biomedical is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Clearside Biomedical's expected growth come at a high price?
Raw Data
NasdaqGM:CLSD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.98x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
-1.9%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.91x
United States of America Market PEG Ratio Median Figure of 2,006 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Clearside Biomedical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Clearside Biomedical's assets?
Raw Data
NasdaqGM:CLSD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.25
NasdaqGM:CLSD Share Price * NasdaqGM (2020-04-02) in USD $1.6
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 182 Publicly-Listed Pharmaceuticals Companies 2.43x
United States of America Market PB Ratio Median Figure of 5,140 Publicly-Listed Companies 1.25x
NasdaqGM:CLSD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:CLSD Share Price ÷ Book Value per Share (both in USD)

= 1.6 ÷ 0.25

6.37x

* Primary Listing of Clearside Biomedical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Clearside Biomedical is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Clearside Biomedical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Clearside Biomedical has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Clearside Biomedical expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-1.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Clearside Biomedical expected to grow at an attractive rate?
  • Unable to compare Clearside Biomedical's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Clearside Biomedical's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Clearside Biomedical's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:CLSD Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:CLSD Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts -1.9%
NasdaqGM:CLSD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 53.1%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.5%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:CLSD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:CLSD Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 59 -39 4
2023-12-31 37 -24 4
2022-12-31 15 -22 5
2021-12-31 7 -21 5
2020-12-31 2 -22 5
2020-04-03
NasdaqGM:CLSD Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 2 -27 -31
2019-09-30 0 -53 -49
2019-06-30 0 -67 -67
2019-03-31 0 -76 -82
2018-12-31 0 -79 -83
2018-09-30 0 -70 -78
2018-06-30 0 -64 -72
2018-03-31 0 -56 -65
2017-12-31 0 -51 -59
2017-09-30 0 -42 -52
2017-06-30 0 -35 -39
2017-03-31 0 -29 -31

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Clearside Biomedical is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Clearside Biomedical's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:CLSD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Clearside Biomedical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CLSD Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.90 -0.27 -1.52 2.00
2023-12-31 -0.60 -0.52 -0.68 2.00
2022-12-31 -0.57 -0.42 -0.74 3.00
2021-12-31 -0.53 -0.46 -0.57 3.00
2020-12-31 -0.54 -0.38 -0.70 4.00
2020-04-03
NasdaqGM:CLSD Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.81
2019-09-30 -1.39
2019-06-30 -1.96
2019-03-31 -2.51
2018-12-31 -2.69
2018-09-30 -2.67
2018-06-30 -2.63
2018-03-31 -2.54
2017-12-31 -2.33
2017-09-30 -2.15
2017-06-30 -1.71
2017-03-31 -1.64

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Clearside Biomedical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Clearside Biomedical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Clearside Biomedical has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Clearside Biomedical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Clearside Biomedical's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Clearside Biomedical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Clearside Biomedical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Clearside Biomedical's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Clearside Biomedical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Clearside Biomedical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CLSD Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 2.17 -30.77 16.82 15.66
2019-09-30 0.26 -49.31 17.35 34.44
2019-06-30 0.12 -66.65 17.44 51.79
2019-03-31 0.08 -81.62 15.99 65.88
2018-12-31 0.03 -82.82 14.68 68.29
2018-09-30 0.06 -77.67 12.95 64.74
2018-06-30 0.21 -72.14 11.37 60.71
2018-03-31 0.34 -65.21 10.10 54.84
2017-12-31 0.35 -58.98 9.70 49.05
2017-09-30 0.30 -52.17 9.65 42.09
2017-06-30 0.15 -39.48 8.98 29.72
2017-03-31 0.02 -30.81 7.66 22.46
2016-12-31 0.52 -25.88 6.26 19.46
2016-09-30 0.52 -21.37 5.09 16.28
2016-06-30 0.51 -19.20 4.53 14.91
2016-03-31 0.51 -19.33 6.58 13.04
2015-12-31 -17.64 6.56 10.76
2015-09-30 -15.13 6.07 8.88
2015-06-30 -14.79 5.67 8.79
2015-03-31 -12.17 3.86 7.75
2014-12-31 -10.19 3.13 6.69
2014-09-30 -9.47 2.93 6.17
2014-06-30 -8.34 2.82 5.40
2014-03-31 -7.69 2.25 5.42
2013-12-31 -7.25 2.19 5.05

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Clearside Biomedical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Clearside Biomedical has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Clearside Biomedical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Clearside Biomedical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Clearside Biomedical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Clearside Biomedical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Clearside Biomedical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Clearside Biomedical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Clearside Biomedical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Clearside Biomedical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 4.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Clearside Biomedical Company Filings, last reported 3 months ago.

NasdaqGM:CLSD Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 11.16 5.15 22.60
2019-09-30 9.76 10.16 22.55
2019-06-30 12.90 10.10 26.17
2019-03-31 16.09 10.04 34.94
2018-12-31 23.62 9.98 40.88
2018-09-30 44.08 9.91 64.94
2018-06-30 66.67 9.85 84.43
2018-03-31 85.93 7.31 101.06
2017-12-31 21.42 8.01 37.64
2017-09-30 36.90 7.90 52.63
2017-06-30 54.33 7.80 66.04
2017-03-31 67.16 7.69 77.45
2016-12-31 71.66 7.59 83.63
2016-09-30 46.94 7.49 56.92
2016-06-30 45.90 5.69 55.28
2016-03-31 5.47 6.04 15.89
2015-12-31 10.66 5.98 20.28
2015-09-30 -4.33 5.92 4.19
2015-06-30
2015-03-31 7.62 0.00 8.27
2014-12-31 7.62 0.00 8.27
2014-09-30 10.16 0.00 11.07
2014-06-30 -2.76 2.93 1.45
2014-03-31 -0.53 0.27 0.53
2013-12-31 1.13 0.27 1.91
  • Clearside Biomedical's level of debt (46.2%) compared to net worth is high (greater than 40%).
  • Unable to establish if Clearside Biomedical's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Clearside Biomedical has less than a year of cash runway based on current free cash flow.
  • Unable to confirm if Clearside Biomedical has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Clearside Biomedical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Clearside Biomedical has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Clearside Biomedical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Clearside Biomedical dividends.
If you bought $2,000 of Clearside Biomedical shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Clearside Biomedical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Clearside Biomedical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:CLSD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1943 Stocks 3.1%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:CLSD Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-03

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Clearside Biomedical has not reported any payouts.
  • Unable to verify if Clearside Biomedical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Clearside Biomedical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Clearside Biomedical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Clearside Biomedical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Clearside Biomedical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Clearside Biomedical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Clearside Biomedical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
George Lasezkay
COMPENSATION $150,157
AGE 67
TENURE AS CEO 1 years
CEO Bio

Dr. George M. Lasezkay, Pharm.D, & J.D. has been Chief Executive Officer at Clearside BioMedical, Inc. since January 2020, serves as President since March 1, 2020 and served as its Interim Chief Executive Officer since April 8, 2019 until January 2020. He serves as Principal of Turning Point Consultants LLC. Dr. Lasezkay has an accomplished history of success in the life sciences industry. Dr. Lasezkay served as an Executive Vice President of Legal Affairs at Acucela Inc. since August 24, 2015 until July 2016 and served as its General Counsel from August 2015 until June 16, 2016. He headed Acucela’s legal team and is the primary legal advisor to Chief Executive Officer and rest of its Executive Team. He managed all aspects of the Acucela’s legal matters, including legal aspects of the strategic partnerships and alliances, risk management and compliance. He actively contributed to the development and execution of corporate alliance strategy as part of the Executive Team. Dr. Lasezkay served as the President of Horizon Pharma Consulting Group from 2005 to December 2015. Dr. Lasezkay served at Allergan from 1989 to 2002, including seven years in its legal department. He served as Assistant General Counsel for Commercial Affairs of Allergan Inc. from 1994 to 1996. He served as Corporate Vice President for Business and Corporate Development of Allergan, Inc., from 1996 to 2002. While at Allergan, he was instrumental in establishing the Allergan Ligand Retinoid Therapeutics joint venture. He participated in and supervised, the negotiation of more than 60 acquisitions, alliances and other collaborations. He served as a Member of the Law Department of Allergan. He was employed at Allergan for 13 years. Dr. Lasezkay has extensive health care industry experience in corporate strategic planning and global business development activities, including the structuring and negotiating of a wide range of biotechnology and pharmaceutical collaborations, product licensing, mergers as well as international and domestic legal issues. Dr. Lasezkay also has extensive experience in hospital pharmacy practice, clinical pharmacokinetics consultation, clinical drug research and pharmacy education. He serves as the Vice President of the Supervisory Board at Novagali Pharma S.A. He serves as an Outside Board Member for several biotech and early stage development companies. He has been a Director at Clearside BioMedical, Inc. since August 8, 2017. He served as a Director at RetroSense Therapeutics, LLC until June 2016. He serves as a director of TheraVida, Inc. He has been a Member of Supervisory Board at Novagali Pharma S.A. since November 18, 2005. He served as an Independent Director of Amakem NV from May 2012 to August 2015. He served as a Director of Acuity Pharmaceuticals, Inc. since 2003. He served as a Director of Collagenex Pharmaceuticals, Inc. from September 22, 2005 to April 10, 2008 and Urigen Pharmaceuticals, Inc. from May 2004 to December 1, 2009. He served as a Director of Valentis Inc., since May 24, 2004. He served as a Director of Sucampo Pharmaceuticals, Inc. He served as a Director of ISTA Pharmaceuticals, Inc. since June 2000. He also served on the boards of a number of U.S. and European biotechnology and pharmaceutical companies, both public and private, including several focused on ophthalmic diseases. He served as Executive Vice President of Legal Affairs at Kubota Pharmaceutical Holdings Co., Ltd. since August 24, 2015 until June 16, 2016 and served as its General Counsel until July 2016. Dr. Lasezkay served as a Member of Strategic Advisory Board at Ico Therapeutics Inc. since November 30, 2005. He is an Adjunct Professor of Pharmaceutical Law and Policy at the University of San Diego School of Law since January 2013. He was an Assistant Professor of Pharmacy at the State University of New York at Buffalo School of Pharmacy. He also holds a certificate in alternative dispute resolution from the Straus Institute of Dispute Resolution of the Pepperdine University School of Law. Dr. Lasezkay holds B.S. Pharmacy and Doctor of Pharmacy degrees from the University at Buffalo in year 1969-1974 and 1976-1978 respectively and a Juris Doctor degree in Law from the University of Southern California Gould School of Law in year 1983-1986. He also has completed selected executive education programs at Northwestern University, Stanford University and the Wharton Business School.

CEO Compensation
  • George's compensation has been consistent with company performance over the past year, both up more than 20%.
  • George's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Clearside Biomedical management team in years:

1.6
Average Tenure
53.5
Average Age
  • The average tenure for the Clearside Biomedical management team is less than 2 years, this suggests a new team.
Management Team

George Lasezkay

TITLE
President
COMPENSATION
$150K
AGE
67
TENURE
1 yrs

Charlie Deignan

TITLE
Chief Financial Officer
COMPENSATION
$434K
AGE
55
TENURE
8.3 yrs

Jenny Kobin

TITLE
Head of Investor Relations
AGE
52

Leslie Zacks

TITLE
General Counsel
AGE
50
TENURE
1.6 yrs

Rick McElheny

TITLE
Vice President of Corporate Development
TENURE
2.3 yrs

Thomas Ciulla

TITLE
Chief Medical Officer
TENURE
1.5 yrs
Board of Directors Tenure

Average tenure and age of the Clearside Biomedical board of directors in years:

3.4
Average Tenure
61
Average Age
  • The tenure for the Clearside Biomedical board of directors is about average.
Board of Directors

Bill Humphries

TITLE
Chairman of the Board
COMPENSATION
$177K
AGE
53
TENURE
2.2 yrs

George Lasezkay

TITLE
President
COMPENSATION
$150K
AGE
67
TENURE
2.7 yrs

Mark Prausnitz

TITLE
Chairman of the Scientific Advisory Board

Clay Thorp

TITLE
Independent Director
COMPENSATION
$148K
AGE
51
TENURE
8.3 yrs

Rick Croarkin

TITLE
Independent Director
COMPENSATION
$158K
AGE
65
TENURE
4.2 yrs

Hank Edelhauser

TITLE
Member of the Scientific Advisory Board

Harold Shlevin

TITLE
Member of the Scientific Advisory Board
AGE
69

Christy Shaffer

TITLE
Independent Director
COMPENSATION
$140K
AGE
61
TENURE
8.3 yrs

Jeff Edwards

TITLE
Independent Director
COMPENSATION
$119K
AGE
58
TENURE
1.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
13. Nov 19 Buy Charles Deignan Individual 12. Nov 19 12. Nov 19 7,500 $1.14 $8,550
12. Nov 19 Buy George Lasezkay Individual 11. Nov 19 11. Nov 19 12,000 $1.16 $13,920
X
Management checks
We assess Clearside Biomedical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Clearside Biomedical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Type Of Shareholder Owns Clearside Biomedical, Inc.'s (NASDAQ:CLSD)?

View our latest analysis for Clearside Biomedical NasdaqGM:CLSD Ownership Summary, August 15th 2019 What Does The Institutional Ownership Tell Us About Clearside Biomedical? … Insider Ownership Of Clearside Biomedical The definition of an insider can differ slightly between different countries, but members of the board of directors always count. … Insider ownership is positive when it signals leadership are thinking like the true owners of the company.

Simply Wall St -

Those Who Purchased Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago Have A 90% Loss To Show For It

So spare a thought for the long term shareholders of Clearside Biomedical, Inc. … A Different Perspective Over the last year, Clearside Biomedical shareholders took a loss of 90%. … Shareholders have lost 47% per year over the last three years, so the share price drop has become steeper, over the last year; a potential symptom of as yet unsolved challenges.

Simply Wall St -

How Much Are Clearside Biomedical, Inc. (NASDAQ:CLSD) Insiders Spending On Buying Shares?

The Last 12 Months Of Insider Transactions At Clearside Biomedical. … In the last twelve months insiders paid US$206k for 27.00k shares purchased. … In the last twelve months there was more buying than selling by Clearside Biomedical insiders

Simply Wall St -

Do Insiders Own Shares In Clearside Biomedical, Inc. (NASDAQ:CLSD)?

Every investor in Clearside Biomedical, Inc. … With a market capitalization of US$40m, Clearside Biomedical is a small cap stock, so it might not be well known by many institutional investors. … View our latest analysis for Clearside Biomedical

Simply Wall St -

Did Clearside Biomedical Inc (NASDAQ:CLSD) Insiders Buy Up More Shares?

So shareholders might well want to know whether insiders have been buying or selling shares in Clearside Biomedical Inc (NASDAQ:CLSD). … Clearside Biomedical Insider Transactions Over The Last Year. … Overall, Clearside Biomedical insiders were net buyers last year

Simply Wall St -

Is Clearside Biomedical Inc (NASDAQ:CLSD) Potentially Underrated?

Clearside Biomedical Inc (NASDAQ:CLSD) is a stock with outstanding fundamental characteristics. … When we build an investment case, we need to look at the stock with a holistic perspective. … In the case of CLSD, it

Simply Wall St -

What Investors Should Know About Clearside Biomedical Inc's (NASDAQ:CLSD) Financial Strength

While small-cap stocks, such as Clearside Biomedical Inc (NASDAQ:CLSD) with its market cap of US$243.06m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … Evaluating financial health as part of your investment thesis is

Simply Wall St -

Clearside Biomedical Inc's (NASDAQ:CLSD) Path To Profitability

Clearside Biomedical Inc's (NASDAQ:CLSD):. … Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. … The US$330.97m market-cap posted a loss in its most recent financial year of -US$58.97m and a latest trailing-twelve-month loss of -US$65.21m leading to an even wider gap between loss and breakeven?

Simply Wall St -

Should Clearside BioMedical Inc's (NASDAQ:CLSD) Recent Earnings Decline Worry You?

View our latest analysis for Clearside BioMedical Despite a decline, did CLSD underperform the long-term trend and the industry? … For Clearside BioMedical, its most recent earnings (trailing twelve month) is -US$52.17M, which, against the prior year's figure, has become more negative. … NasdaqGM:CLSD Income Statement Mar 14th 18 We can further assess Clearside BioMedical's loss by looking at what the industry has been experiencing over the past few years.

Simply Wall St -

Analysts Expect Breakeven On The Horizon For Clearside BioMedical Inc (NASDAQ:CLSD)

Many investors are wondering the rate at which CLSD will turn a profit, with the big question being “when will the company breakeven?” Below I will provide a high-level summary of the industry analysts’ expectations for CLSD. … See our latest analysis for Clearside BioMedical Expectation from analysts is CLSD is on the verge of breakeven. … It turns out an average annual growth rate of 25.37% is expected, which signals high confidence from analysts.

Simply Wall St -

Company Info

Description

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.

Details
Name: Clearside Biomedical, Inc.
CLSD
Exchange: NasdaqGM
Founded: 2011
$71,789,692
44,868,558
Website: http://www.clearsidebio.com
Address: Clearside Biomedical, Inc.
900 North Point Parkway,
Suite 200,
Alpharetta,
Georgia, 30005,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM CLSD Common Stock Nasdaq Global Market US USD 02. Jun 2016
BST CLM Common Stock Boerse-Stuttgart DE EUR 02. Jun 2016
Number of employees
Current staff
Staff numbers
33
Clearside Biomedical employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/03 02:31
End of day share price update: 2020/04/02 00:00
Last estimates confirmation: 2020/03/13
Last earnings filing: 2020/03/13
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.